November 1, 2010
If your application had system-identified errors and did not make it through the eRA Commons application checking process (i.e., checking against NIH business rules), you must correct the errors and submit a changed/corrected application to Grants.gov before your application can be accepted by NIH for review. Follow these steps to submit a changed/corrected application to … Continue reading “How Do I Correct Errors During the Application Submission Process?”
October 1, 2010
The margins (top, bottom, left, and right) should be at least 1/2 inch.
October 1, 2010
Arial, Helvetica, Palatino Linotype, or Georgia typeface, black color, and a size of 11 points or larger should be used. A symbol font may be used to insert Greek letters or special characters, but the font size requirement still applies.
October 1, 2010
File names are limited to 50 characters or less. Please be sure to only use standard characters in file names: A through Z, a through z, 0 through 9, and underscore (_). Do not use any special characters (e.g., &, -, *, %, /, and #) or spacing in the file name. For word separation, … Continue reading “Does the File Name of the Application Have a Maximum Length?”
October 1, 2010
The Project Summary/Abstract is limited to 30 lines of text and must follow the required font and margin specifications.
October 1, 2010
The descriptive title is limited to 81 characters (including the spaces between words and punctuation). Titles in excess of 81 characters will be truncated. Be sure to only use standard characters [A through Z, a through z, 0 through 9, and underscore (_)].
September 1, 2010
A PI can check the status of their application by logging in to their eRA Commons account.
September 1, 2010
No. The continuous submission policy only applies to R01, R21 and R34 applications submitted for the standard due dates. It does not apply to applications submitted for RFAs and PARs with special due dates.
September 1, 2010
Yes. For more information on the continuous submission policy, see NOT-OD-09-114.
0 Comments